Effect of periodontal therapy on specific antibody responses to suspected periodontopathogens.
The effects of clinically successful periodontal therapy were studied in juvenile periodontitis (JP) and rapidly progressive periodontitis (RP) patients and compared with periodontally healthy subjects (HS). Serum samples were obtained in 35 HS prior to the study and in 12 of these subjects 3-4 years later. Serum samples were obtained from 50 JP patients initially, 9 subjects immediately following surgical therapy and 29 of these subjects 3-4 years later. RP patients provided 46 initial serum samples, 9 following therapy and 27 samples 3-4 years later. Antibody levels were determined utilizing a standardized enzyme-linked immunosorbent assay with Bacteroides gingivalis, B. ochracea, Fusobacterium nucleatum and Actinobacillus actinomycetemcomitans serving as antigens. The JP patients showed an initial rise in antibody levels immediately following therapy followed by a significant decrease in antibody levels 3 to 4 years later. The RP patients did not show an early change in antibody levels but by 3 to 4 years post-therapy, antibody levels had significantly decreased. However, during this study, the antibody levels of JP and RP patients remained significantly higher when compared with HS patients.
D000188:Actinobacillus / Q000276:immunology; D000293:Adolescent; D000328:Adult; D010520:Aggressive Periodontitis / Q000276:immunology / Q000628:therapy*; D000907:Antibodies, Bacterial / Q000032:analysis*; D001419:Bacteria / Q000276:immunology*; D001439:Bacteroides / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D005673:Fusobacterium / Q000276:immunology; D006801:Humans; D010510:Periodontal Diseases / Q000628:therapy*; D010518:Periodontitis / Q000276:immunology / Q000628:therapy*
D000907:Antibodies, Bacterial